Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
出版年份 2022 全文链接
标题
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
作者
关键词
-
出版物
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-22
DOI
10.1007/s11010-022-04474-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
- (2022) Alison K. Wright et al. DIABETES CARE
- A Glucagon-like Peptide 1 Analogue Protects Mitochondria and Attenuates Hypoxia-reoxygenation Injury in Cultured Cardiomyocytes
- (2022) Miyuki Kobara et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
- (2021) Elisabetta Patorno et al. DIABETES CARE
- Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
- (2021) Ryan Pelletier et al. Therapeutic Advances in Drug Safety
- Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
- (2021) Peter M. Becher et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
- (2021) Xiaodan Wang et al. HEART FAILURE REVIEWS
- Cardiac substrate utilization in heart failure – where is the relevance of SGLT2 inhibition
- (2021) Pascal Alexander Mann et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
- (2021) Hang-Long Li et al. Cardiovascular Diabetology
- Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
- (2021) Giulia Ferrannini et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
- (2021) Gilson C. Fernandes et al. HEART RHYTHM
- Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
- (2021) Hideaki Kaneto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GLP‐1 receptor agonist treatment of high‐carbohydrate intake‐induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca 2+ abnormalities and mitochondrial dysfunction
- (2021) Aysegul Durak et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
- (2021) Emily Brown et al. LANCET
- Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
- (2021) Dominique Croteau et al. Journal of the American Heart Association
- Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
- (2021) Kai-Fan Tsai et al. Antioxidants
- Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
- (2021) Vaia Lambadiari et al. Antioxidants
- Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
- (2021) Gloria M. Gager et al. BIOMEDICINE & PHARMACOTHERAPY
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
- (2021) Andrea Natali et al. Cardiovascular Diabetology
- Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond
- (2021) Angela Sciacqua et al. HEART FAILURE REVIEWS
- Insulin acts as an atypical KCNQ1/KCNE1‐current activator and reverses long QT in insulin‐resistant aged rats by accelerating the ventricular action potential repolarization through affecting the β 3 ‐adrenergic receptor signaling pathway
- (2021) Yusuf Olgar et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
- (2021) Sean Wharton et al. POSTGRADUATE MEDICINE
- Review of Insulin Resistance in Dilated Cardiomyopathy and Implications for the Pediatric Patient Short Title: Insulin Resistance DCM and Pediatrics
- (2021) Daniel Mak et al. Frontiers in Pediatrics
- The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms
- (2021) Jennifer Y. Barraclough et al. Cells
- Highlights in heart failure
- (2020) Daniela Tomasoni et al. ESC Heart Failure
- Titin and CK2α are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats
- (2020) Aysegul Durak et al. CARDIOVASCULAR DRUGS AND THERAPY
- MitoTEMPO provides an antiarrhythmic effect in aged-rats through attenuation of mitochondrial reactive oxygen species
- (2020) Yusuf Olgar et al. EXPERIMENTAL GERONTOLOGY
- Ageing‐associated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca 2+ homeostasis and promotes cardiac dysfunction
- (2020) Yusuf Olgar et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- (2020) Martin R. Cowie et al. Nature Reviews Cardiology
- Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels
- (2020) Xiao-Jie Bai et al. CARDIOVASCULAR DRUGS AND THERAPY
- GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
- (2020) Lili Zhang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency
- (2019) Kim L Ho et al. CARDIOVASCULAR RESEARCH
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics
- (2019) Masao Saotome et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role and mechanism of cardiac insulin resistance in occurrence of heart failure caused by myocardial hypertrophy
- (2019) Liling Zheng et al. Aging-US
- Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism
- (2019) Wen-Chin Lee et al. Cells
- GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
- (2019) Qian-Feng Xiong et al. Cardiology Research and Practice
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
- (2019) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats
- (2018) Piangkwan Sa-nguanmoo et al. BIOMEDICINE & PHARMACOTHERAPY
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
- (2018) Vaia Lambadiari et al. Cardiovascular Diabetology
- Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat
- (2018) Firas Younis et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Decreased ATP production and myocardial contractile reserve in metabolic heart disease
- (2018) Ivan Luptak et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Age-associated Changes in the Respiratory Epithelial Response to Influenza Infection
- (2018) Kelly D Chason et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
- (2018) Edison Goncalves et al. Diabetes Therapy
- Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
- (2018) Edison Goncalves et al. Diabetes Therapy
- A Brief Overview from the Physiological and Detrimental Roles of Zinc Homeostasis via Zinc Transporters in the Heart
- (2018) Belma Turan BIOLOGICAL TRACE ELEMENT RESEARCH
- Association between insulin resistance and the development of cardiovascular disease
- (2018) Valeska Ormazabal et al. Cardiovascular Diabetology
- A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
- (2018) Yusuf Olgar et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
- (2018) Aysegul Durak et al. Cardiovascular Diabetology
- Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.
- (2018) Hiroto Oshima et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
- (2018) Giulia Borghetti et al. Frontiers in Physiology
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Association between elevated blood glucose level on admission and long-term mortality in patients with acute decompensated heart failure
- (2017) Sharma Kattel et al. Journal of Cardiology
- Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure
- (2017) Cathy A Guo et al. JOURNAL OF ENDOCRINOLOGY
- Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway
- (2017) Jingjing Chen et al. PEPTIDES
- Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
- (2017) Cristina Barale et al. THROMBOSIS AND HAEMOSTASIS
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus
- (2016) Cecilia C. Low Wang et al. CIRCULATION
- Insulin Signaling and Heart Failure
- (2016) Christian Riehle et al. CIRCULATION RESEARCH
- Mitochondrial Metabolism in Aging Heart
- (2016) Edward J. Lesnefsky et al. CIRCULATION RESEARCH
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes
- (2016) Jen-Hung Huang et al. PEPTIDES
- Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study
- (2015) Federica Ciregia et al. Molecular BioSystems
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcium and ROS: A mutual interplay
- (2015) Agnes Görlach et al. Redox Biology
- Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis
- (2015) Allison A. Lambert et al. PLoS One
- GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum–mitochondria coupling
- (2014) Pablo E. Morales et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells
- (2014) Makiko Ogata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Heart failure-specific changes in protein kinase signalling
- (2014) Kristina Lorenz et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
- (2013) Sihem Boudina CURRENT PHARMACEUTICAL DESIGN
- Myocardial Loss of IRS1 and IRS2 Causes Heart Failure and Is Controlled by p38 MAPK During Insulin Resistance
- (2013) Y. Qi et al. DIABETES
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
- (2013) D. Wang et al. DIABETES
- Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
- (2013) Elizabeth M Lamos et al. Expert Opinion on Drug Metabolism & Toxicology
- Animal models of insulin resistance and heart failure
- (2013) Mauricio Velez et al. HEART FAILURE REVIEWS
- Signaling effectors underlying pathologic growth and remodeling of the heart
- (2013) Jop H. van Berlo et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
- (2012) M. Burgmaier et al. DIABETIC MEDICINE
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation
- (2012) Cheryl D. Waring et al. EUROPEAN HEART JOURNAL
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Insulin Resistance and Heart Failure
- (2012) Annayya R. Aroor et al. Heart Failure Clinics
- Glucagon-like peptide 1 and cardiac cell survival
- (2012) Susana Ravassa et al. Endocrinologia y Nutricion
- A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index
- (2011) Ian F. Godsland et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
- (2011) Hui-Chun Ku et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes
- (2011) Eva Tomas et al. REGULATORY PEPTIDES
- Aging-Associated Cardiovascular Changes and Their Relationship to Heart Failure
- (2011) James B. Strait et al. Heart Failure Clinics
- Understanding the Cardiovascular Effects of Incretin
- (2011) Ji Sung Yoon et al. Diabetes & Metabolism Journal
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
- (2010) Kiwon Ban et al. ENDOCRINOLOGY
- Glucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons
- (2010) g. g. gaisano et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
- (2009) Jens Kristensen et al. BMC Cardiovascular Disorders
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Serum glucose and insulin are associated with QTc and RR intervals in nondiabetic elderly
- (2009) Charlotte van Noord et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
- (2009) Manfredi Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
- Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
- (2008) M Marzioni et al. GUT
- Insulin-Resistant Cardiomyopathy
- (2008) Ronald M. Witteles et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global public health: a scorecard
- (2008) Robert Beaglehole et al. LANCET
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started